Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
621-640 of 1,743 trials

Quizartinib for Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia

We are studying whether quizartinib, combined with chemotherapy, can improve survival in adults with newly diagnosed FLT3-ITD negative AML compared to a placebo. This trial aims to assess its effectiveness and safety.

Acute Myeloid Leukemia>2 yearsConfirmation phase (III)Standard MedicinesCost ReimbursementOncology

Biliary Tract Cancers: [18F]F-FAPI PET-CT Imaging Study

We are investigating how a new imaging technique may improve diagnosis and treatment planning for patients with potentially resectable biliary tract cancers. This study will also look at the cost-effectiveness and safety of this imaging method.

Cholangiocarcinoma>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyOncology

Colchicine for Angina in Microvascular Disease

We are studying whether colchicine can improve blood flow and reduce symptoms in patients with angina caused by coronary microvascular dysfunction. This research may help us understand how to better treat this condition.

Cardiovascular Disease (CMD)>2 yearsEfficacy phase (II)Standard MedicinesCardiology

Pompe Disease: Enzyme Replacement Therapy Study

We are examining how a new enzyme replacement therapy affects muscle glycogen in people with Pompe disease who have not yet received treatment. This research may help improve future therapies for this condition.

Pompe's Disease>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementEndocrinologyHematologyNeurology

DZR123 for Advanced Solid Tumors and Lymphomas

We are studying a new treatment called DZR123 for patients with advanced solid tumors and lymphomas. The trial will help us understand its safety and how well it works alone and with another medication.

Advanced Solid Tumors and Lymphomas>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Eosinophilic Granulomatosis with Polyangiitis: Mepolizumab Treatment

We are studying how mepolizumab affects the nasal microbiome and immune response in patients with eGPA. This research may help understand its impact on local inflammation in the ENT area.

Eosinophilic Granulomatosis with Polyangiitis (eGPA)>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesOtolaryngology

Biliary Tract Cancer: T-DXd and Rilvegostomig Study

We are studying a new treatment combination for patients with advanced HER2-expressing biliary tract cancer. The goal is to see if it helps improve survival compared to standard care options.

Advanced HER2-expressing Biliary Tract Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Colorectal Cancer: NILK-2301 Antibody Study

We are testing a new antibody treatment for patients with colorectal cancer to see how safe it is and how well it works. This study aims to gather important information for future treatments.

Locally Advanced or Metastatic Low Tumor Volume Colorectal Cancer>2 yearsSafety phase (I)GastroenterologyOncology

Dupilumab for Chronic Rhinosinusitis with Nasal Polyps

We are studying how dupilumab affects ear symptoms and hearing in patients with chronic rhinosinusitis and eosinophilic otitis media. This research aims to improve understanding of treatment benefits for these conditions.

Chronic Rhinosinusitis with Nasal PolypsEosinophilic Otitis Media>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesAllergologyOtolaryngology

Advanced Colon Cancer: Preoperative Chemotherapy Study

We are investigating whether chemotherapy before surgery is more effective than surgery followed by additional treatment for advanced colon cancer. This trial aims to improve treatment strategies for patients.

Colon Cancer (Stage T3-4)>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyOncology

Polymyalgia Rheumatica: Secukinumab Safety Study

We are evaluating the long-term safety of secukinumab for individuals with polymyalgia rheumatica. This study will help us understand any potential side effects associated with this treatment.

Polymyalgia Rheumatica>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineRheumatology

Childhood Absence Epilepsy: Brivaracetam Safety Study

We are studying the long-term safety of brivaracetam in children and young adults with childhood or juvenile absence epilepsy. This research aims to understand how well the medication is tolerated over time.

Childhood Absence EpilepsyJuvenile Absence Epilepsy>2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteNeurologyPediatrics

Advanced Biliary Cancer: Personalized Targeted Therapy

We are studying whether a new personalized treatment can help patients with advanced biliary cancer live longer without disease progression compared to standard care. This trial also examines the quality of life and safety of the new therapies.

Advanced Biliary Cancer>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesInternal MedicineOncology

Lymphoblastic Lymphoma: New Treatment Protocol for Kids

We are studying whether changing medications during treatment can help reduce relapses in the brain for children and adolescents with lymphoblastic lymphoma. This trial aims to improve survival rates and treatment outcomes compared to standard approaches.

Lymphoblastic Lymphoma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

Long-Term Follow-Up of CAR T-Cell Therapy Patients

We are studying the long-term effects and safety of CAR T-cell therapy in patients who have received this treatment. This includes monitoring for delayed side effects and the persistence of modified T-cells in the blood.

Multiple MyelomaB-cell LymphomaB-cell Type Acute Leukaemia>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Chronic Myeloid Leukemia: Asciminib for Kids

We are studying the safety and appropriate dose of asciminib in children with chronic myeloid leukemia. This research aims to ensure the medication is safe and effective for young patients who have already tried other treatments.

Philadelphia Positive Chronic Myeloid Leukemia>2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncologyPediatrics

Methylprednisolone for Infants with Neuroendocrine Cells Hyperplasia

We are studying whether methylprednisolone pulses can reduce the need for oxygen therapy in infants with NEHI. The trial also examines the treatment's effects on respiratory health and quality of life.

Neuroendocrine Cell Hyperplasia of Infancy>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteInternal MedicinePulmonology

Alpha-1 Antitrypsin Deficiency Emphysema: SAR447537 Study

We are studying the long-term safety of SAR447537 in adults with alpha-1 antitrypsin deficiency emphysema. The trial will also evaluate its effects on lung health and how the body processes the treatment.

Alpha-1 Antitrypsin Deficiency (AATD) Emphysema>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicinePulmonology

Intrathecal Baclofen for Spinal Cord Injury: Safety Study

We are investigating whether intrathecal baclofen is safe for spinal cord injury patients, particularly regarding lung function and sleep disorders. The study also looks at its potential to reduce muscle stiffness and improve daily activities.

Spinal Cord Injury>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesNeurologyPulmonology

Thrombosis Prevention in Surgery: Apixaban Study

We are studying whether the medication apixaban can help prevent blood clots in patients undergoing general abdominal, gynecologic, and urologic surgeries. This trial compares its effects to not using any anticoagulants during surgery.

Venous Thromboembolism>2 yearsMonitoring phase (IV)Standard MedicinesPartially RemoteGynecology and ObstetricsInternal MedicineOrthopedics and TraumatologyUrology